FDA clears UltraSPECT's PET application

Justine Varieur Cadet | | Health Imaging | Molecular Imaging
The FDA has cleared UltraSPECT’s Xpress.PET product, a whole-body PET application, which will be offered for sale immediately in the U.S. market.

Xpress.PET is based on UltraSPECT's Wide-Beam Reconstruction (WBR) technology. The Auburndale, Mass.-based company said its WBR products for gamma cameras have been utilized for cardiac and oncology applications in the U.S. and Europe since 2005. The new Xpress.PET expands the WBR product family with additional modality applications.

Justine Varieur Cadet

Related Content

Researchers receive grant worth millions to develop portable PET scanner
Why is the US still dependent on foreign medical isotope production?
Downed high-flux reactor could restart sooner than anticipated
Some nuc med departments are already feeling the strain of the isotope shortage
NorthStar opens facility to assist with development and distribution of vital radioisotopes
Lizard saliva could be key to spotting elusive pancreatic tumors

Around the web

Radiology Business
Key Medicare reimbursement and No Surprises Act updates from RSNA 2024

Richard Heller III, MD, RSNA board member and senior VP of policy at Radiology Partners, offers an overview of policies in Congress that are directly impacting imaging.
 

Cardiovascular Business
Philips, Mayo Clinic using AI to improve cardiac MRI technology

The two companies aim to improve patient access to high-quality MRI scans by combining their artificial intelligence capabilities.

Cardiovascular Business
Positron partners with Upbeat Cardiology Solutions to improve cardiac PET/CT access

Positron, a New York-based nuclear imaging company, will now provide Upbeat Cardiology Solutions with advanced PET/CT systems and services.